A NEW HAEMODIALYSIS CATHETER-LOCKING AGENT REDUCES INFECTIONS IN HAEMODIALYSIS PATIENTS
| Autor: | Caroline Taylor, Jane Little, Martin Gerrish, John Cahill |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Taurine medicine.drug_class Population Antibiotics Sepsis chemistry.chemical_compound Catheters Indwelling Cost of Illness Renal Dialysis Humans Medicine Prospective Studies Therapeutic Irrigation education Prospective cohort study Aged Aged 80 and over Advanced and Specialized Nursing Cross Infection Infection Control education.field_of_study Chi-Square Distribution Cross-Over Studies Thiadiazines business.industry Incidence Incidence (epidemiology) Equipment Design Middle Aged Taurolidine medicine.disease Crossover study Surgery Catheter Logistic Models England chemistry Nephrology Multivariate Analysis Anti-Infective Agents Local Equipment Contamination Kidney Failure Chronic Female business |
| Zdroj: | Journal of Renal Care. 34:116-120 |
| ISSN: | 1755-6686 1755-6678 |
| DOI: | 10.1111/j.1755-6686.2008.00027.x |
| Popis: | SUMMARY Background: Intravenous catheters for haemodialysis increase the risk of sepsis. This study investigates the use of a taurolidine/citrate catheter-locking agent for patients receiving hospital-based haemodialysis, auditing the number and cost of infections before and after its introduction. Methods: The incidence and cost of treatment of catheter sepsis occurring in all patients receiving haemodialysis via a line were investigated over 6-month periods before and after introducing the taurolidine/citrate line-locking agent. Results: A reduction of 4.62 infections per 1000 catheter days, or 88.5%, was shown after the introduction of the new line-locking agent. The total costs of line infections in the first 6 months were €52 500, (£41 000); after the introduction of the taurolidine/citrate locks, these reduced to €33 300, (£26 000), a reduction of €19 200 (£15 000). Conclusions: The use of a taurolidine/citrate haemodialysis catheter-locking agent in our haemodialysis population has significantly reduced the line sepsis rate, with a positive impact on morbidity, mortality and cost. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text